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Abstract
Background: The study was aimed to determine the measurement accuracy of The CDI™ blood parameter
monitoring system 500 (Terumo Cardiovascular Systems Corporation, Ann Arbor MI) in the real-time continuous
measurement of arterial blood gases under different cardiocirculatory stress conditions
Methods: Inotropic stimulation (Dobutamine 2.5 and 5 μg/kg/min), vasoconstriction (Arginine-vasopressin 4, 8 and
16 IU/h), hemorrhage (-10%, -20%, -35%, and -50% of the theoretical volemia), and volume resuscitation were
induced in ten swine (57.4 ± 10.7 Kg).Intermittent blood gas assessments were carried out using a routine gas
analyzer at any experimental phase and compared with values obtained at the same time settings during
continuous monitoring with CDI™ 500 system. The Bland-Altman analysis was employed.
Results: Bias and precision for pO2 were - 0.06 kPa and 0.22 kPa, respectively (r
2 = 0.96); pCO2 - 0.02 kPa and 0.15 kPa,
respectively; pH -0.001 and 0.01 units, respectively ( r2 = 0.96). The analysis showed very good agreement for SO2
(bias 0.04,precision 0.33, r2 = 0.95), Base excess (bias 0.04,precision 0.28, r2 = 0.98), HCO3 (bias 0.05,precision 0.62, r
2 =
0.92),hemoglobin (bias 0.02,precision 0.23, r2 = 0.96) and K+ (bias 0.02, precision 0.27, r2 = 0.93). The sensor was
reliable throughout the experiment during hemodynamic variations.
Conclusions: Continuous blood gas analysis with the CDI™ 500 system was reliable and it might represent a new
useful tool to accurately and timely monitor gas exchange in critically ill patients. Nonetheless, our findings need
to be confirmed by larger studies to prove its reliability in the clinical setting.
Background
Blood gas monitoring is essential for the management of
critically ill patients, providing valuable information
about the state of the patient’s oxygenation, gas
exchange, ventilation and acid-base homeostasis [1].
Despite the rapidity of measurements and automation
of modern blood gas analyzers (BGA), and the need for
only small volumes of blood for any single sample, the
intermittent nature of these measurements may provide
only a snapshot of blood gases fluctuations occurring
even in stable patients in the intensive care unit (ICU)
[2]. This may result in potentially missing short-term
trends, delaying adequate appraisal of ongoing meta-
bolic, respiratory or cardiocirculatory changes, and,
hence, limiting or impeding prompt therapeutic inter-
ventions. In addition the measurements may be inaccu-
rate due to errors in sampling, storage and analysis [3].
Recent advances in technology have shifted the thrust
from intermittent to continuous monitoring with the
result that real time data are available continuously at
the bedside [1].
The CDI™ Blood parameter monitoring system 500
(Terumo Cardiovascular Systems Corporation, Ann
Arbor MI) is an optical fluorescence and reflectance-
based in-line system which is used during cardiopul-
monary bypass (CPB) to provide a reliable estimate of
blood pCO2, pO2, pH and temperature with a 20s time-
constant response [4]. However, whereas most of the
published data on CDI™ 500 give evidence of the accu-
racy of this system during CPB [4,5], no information
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exist on its potential use as continuous blood gas moni-
toring at patient’s bedside.
The aim of this study was to assess the accuracy and
the reliability of the CDI™ 500 in the real-time continu-
ous measurement of arterial blood gases under cardio-
circulatory stress conditions in an animal model as
compared to intermittent blood gas analysis.
Methods
The study was approved by the Institutional Ethics
Committee and animals were managed according to the
principles of the “Guide for the Care and Use of Labora-
tory Animals” and according to the “Guide for the Care
and Use of Laboratory Animals” and in accordance with
the Italian national law (DL. 116/1992) and the recom-
mendations of the European Community (86/609/CEE)
for the care and use of laboratory animals.
Ten healthy swine, (mean weight Kg 57.4 ± 10.7), had
preoperative intramuscular 15 mg/Kg ketamine (Parke
Davis-Pfizer, Karlsruhe, DE) and 5 mg/Kg diazepam
(Roche, Fontenay-sous Bois, France). General anesthesia
was induced with intravenous ketamine (3.5 mg./Kg)
and atropine sulfate 0.05 mg/Kg (Galenica Senese, Siena,
IT). The trachea was intubated during spontaneous
breathing and, after paralysis was obtained with 0.1 mg/
Kg pancuromium bromide (N.V Organon, Oss, NL).
The lungs were ventilated in a volume-controlled mode
(Datex-Ohmeda; Helsinki; Finland) with 40% oxygen
at 16-20 breaths per minute and a tidal volume of
8-10 ml/Kg adjusted to maintain partial carbon dioxide
pressure ranging from 35 to 40 mmHg. Anesthesia was
maintained with sevoflurane (2-3%).The electrocardio-
gram was continuously monitored in a standard DII lead
and oxygen saturation was monitored by a continuous
pulse oxymeter placed on the ear (Datex-Ohmeda;
Helsinki; Finland).
An18-gauge cannula was inserted into the left carotid
artery for intermittent arterial blood sampling, and
blood gas analyses (ABL 825 Flex, Diamond Diagnostic,
Holliston, MA) were carried out by FL: a total of 130
samples were analyzed. Any measurement was corrected
by the animal’s temperature.
An 18-gauge and a 14-gauge cannula were inserted
into the left femoral artery and the femoral vein, respec-
tively, and an arterio-venous loop was created with a
dedicated CDI™ 500 circuit (Figure 1) with a minimum
blood flow of 35 ml/min into the heparin-treated shunt
sensor CDI™ 510H.
The flow was precisely measured by a flow sensor
incorporated into a ECLS pump drive (Rotaflow, Maquet,
Rastatt, Germany) at different levels of arterial blood
pressure (mean 60 ± 20 mmHg). Body temperature, mea-
sured with a rectal probe, was maintained between 37.5°
and 38°C by means of a heating blanket and by warming
the infused solutions. The system updates measurements
every six seconds. A single investigator (FL) collected and
stored in a computer system (Acer Aspire Travel Mate
1690; Acer-Italia, Milan, Italy) data from blood samples
and the corresponding values displayed on the CDI sys-
tem at any time the blood was taken.
The right femoral artery was cannulated with a
standard 18-gauge catheter and connected with the
Most-Care™ monitor powered by Pressure Recording
Analytical Method (PRAM)[6] via a standard pressure
monitoring set (Edwards Lifesciences, Irvine, CA, USA).
The resulting signal was processed by Most-Care™
(Release 1.00A,Vytech Healthcare, Padova, Italy) for the
determination of CO. Most-Care™ was connected to a
corresponding laptop computer (Acer Aspire Travel
Mate 1690; Acer-Italia, Milan, Italy) for continuous
recording of the hemodynamic data (Most-Care Smart
Card reader, Vytech Health™, Padova, Italy).
The PRAM has been validated either in experimental
[6] or clinic studies in unstable patients [7] and it
resulted to be reliable under different hemodynamic
conditions.
The right internal jugular vein was cannulated with a
14-gauge multi-lumen catheter (Three Lumen Central
Venous Catheterization Set. Arrow International,
Inc.2400 Bernville Road, Reading, PA 19605 USA) and
the distal lumen connected to a standard pressure
transducer.
Experimental Protocol
Thirty minutes after the end of preparation, the experi-
mental protocol started and three different hemody-
namic challenges were induced in the following
temporal order:
1) Inotropism, tachycardia and vasodilation (mimick-
ing a physically-related stress test - dobutamine
infusion).
Figure 1 Schematic view of the dedicated CDI circuit (see text).
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2) Peripheral vascular vasoconstriction (Arginine-vaso-
pressin infusion).
3) Hemorrhagic shock (controlled blood loss).
4) Volume cardiocirculatory resuscitation (controlled
fluid loading).
Before starting the dobutamine phase, a baseline blood
sample was taken (B1). The dobutamine phase was per-
formed in two separate 30 minute steps: 2.5 mg/kg/min
(D1) and 5 mg/kg/min (D2). Dobutamine infusion was
then stopped and, when the heart rate returned within
10% of that measured in B1, a new blood sample was
taken during this re-established stable condition (B2)
which was maintained for one hour. Then, three
30 minute steps of vasoconstriction were induced with
arginine-vaso-pressin (AVP) at the doses of 4 IU/h
(AVP1), 8 IU/h (AVP2), and 16 IU/h (AVP3). After one
hour from the end of arginine-vasopressin infusion and
normalization of the mean arterial pressure a new blood
gas analysis was carried out (B3). Hemorrhage was
obtained with a controlled bleeding obtaining four pro-
gressive steps of exsanguinations: H1: -10% circulating
blood, H2 : -20%, H3 : -35%, and H4 : -50% of the theo-
retical volemia Blood volume was estimated as: animal
weight (Kg) × 65 ml/Kg. The blood volume was with-
drawn at a rate that decreased over time in a stepwise
fashion with half of the target hemorrhage volume
occurring in the first 5 min and the remaining volume
over the next 10 min[8]. At 20 min, resuscitated pigs
were administered hydroxyethyl starch 6% (volume
resuscitation, VR). Additional infusions of 5 ml/kg were
provided at 30, 60, 120, and 180 min if hypotension
(MAP < 60 mmHg) or tachycardia (HR > baseline
value)were observed.
The Device
The CDI™ blood parameter monitoring system 500
consists of a monitor to process and display data, a
user-selected combination of blood parameter modules
(BPMs), and hematocrit/oxygen saturation probe (H/S
probe), disposable sterile sensor, H/S cuvette and a
calibrator.
The disposable sensors and/or H/S cuvette are
installed in the cable heads of the BPMs or the H/S
probe, at a point of the circuit will allow adequate expo-
sure to blood. BPMs, which measures Ph, pCO2, pO2
and K+, use optical fluorescence technology in conjunc-
tion with the disposable CDI™ system 500 shunt sensor.
The H/S probe, which measures hematocrit, hemoglobin
and oxygen saturation, uses optical reflectance technol-
ogy in conjunction with the disposable H/S cuvette.
Sensors for Ph, pCO2, pO2 are calibrated using the
CDI calibrator 540 and two canisters of calibration
gases which contain precise, defined levels of pCO2, and
pO2 [9]. To perform the calibration the system measures
the intensities emitted by a micro sensor as it is exposed
to Gas A and Gas B. It them plots these two fluorescent
measurements as a function of the predefined values of
the calibration gases. The system uses the two points to
create a slope and a y-intercept for that parameter. The
measures the fluorescent intensity of the blood and it
uses the slopes and intercept to extrapolate correspond-
ing blood parameter values.
Calibration of K+ also relies on a two-point slope and
intercept calibration process. The slope is defined using
the factory-measured value encoded in the calibration
code entered from the sensor pouch during the initial
calibration sequence. The intercept point is obtained
using the K+ level in an animal blood sample processed
using a laboratory analyzer. The value is then entered in
the CDI™ 500 system to replace the stored reading.
Finally, the H/S probe is pre-calibrated at the factory for
oxygen saturation, hematocrit and hemoglobin. The sys-
tem does not require further re-calibration[9].
Statistical Analysis
All the data were analyzed with Stats Direct
(Relase.2.5.8, Cheshire, UK) and Graph Pad Prism
(Release4.0; San Diego, USA). Hemodynamic variables
at each time point were tested for significant differences
by ANOVA for repeated measures and Bonferroni’s cor-
rection was also applied for a post-hoc analysis. Agree-
ment between intermittent and continuous blood gas
analyses was assessed with a Bland-Altman plot [10]
obtaining: bias (mean difference between methods), pre-
cision (±2 SD of bias) and limits of agreement. The
relationship between the techniques was investigated by
linear regression analysis and Pearson’s correlation
coefficient.
Results
Hemodynamic changes during the experiment are shown
in Table 1. Table 2 displays results of Pearson’s correla-
tion and Bland-Altman analysis: for pO2, the linear
regression between the two methods was r2 = 0.96. Bias
and precision were - 0.06 kPa and 0.22 kPa, respectively.
The analysis of different hemodynamic phases showed a
significant correlation at concurrent point of the experi-
ment. The Bland-Altman analysis is depicted in Figure
2A. The graphical analysis shows an overall homogeneity
between the two methods even at lower arterial pO2
levels. pCO2 measurement revealed a linear regression of
r2 = 0.95 between CDI™ and blood-gas analyzer. Bias
and precision were - 0.02 kPa and 0.15 kPa, respectively.
The Bland-Altman plot (Figure 2B) showed optimal
agreement at corresponding pCO2 values during hemo-
dynamic variations.
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Table 1 Hemodynamic Parameters
Overall B1 D1 D2 B2 AVP1 AVP2 AVP3 B3 H1 H2 H3 H4 VR
COT(L/min) 3.8 ± 1.08 4.3 ± 1.18 4.93 ± 1.5 4.77 ± 1.9 4.17 ± 1.06 3.92 ± 0.96 3.50 ± 1.16 3.17 ± 0.98 * 4.2 ± 0.82 3.8 ± 0.73 2.63 ± 0.67 2.38 ± 0.74 1.9 ± 0.55* 5.17 ± 1.85
†‡§ ||
SV (ml) 44.3 ± 11.52 56.9 ± 14.94 48.8 ± 20.33 40.1 ± 17.95 * 52.1 ± 12.92 54.6 ± 12.71 51.9 ± 11.61 50.4 ± 8.78 59.8 ± 12 45.2 ± 9.2* 29.8 ± 7.9# 26.1 ± 7.9#† 17 ± 4.1#**‡‡ 60.2 ± 9.5††‡§#
HR (bts/min) 85.7 ± 17.9 77.8 ± 23.3 104.8 ± 19.2 * 124.6 ± 14.2 † 81.1 ± 16 72.5 ± 14.1 67.3 ± 16.9 ‡ 62.7 ± 16† 69.1 ± 15.6 84 ± 21.2 88 ± 21.1§ 91.1 ± 18.8* 105.8 ± 16.8#||||
‡‡
85.1 ± 20.2 ##
MAP (mmHg) 55.1 ± 7.03 55.5 ± 3.48 65.1 ± 12.4 60.3 ± 11.9 52 ± 3.5 65.6 ± 8.7* 73.8 ± 9† 76.1 ± 6.7† § 64 ± 8.7 45.1 ± 4.7# 36.8 ± 6.3# † 33 ± 4.4# † 29.6 ± 5# |||| 59.1 ± 6.6||||‡ §||
CVP (mmHg) 8.82 ± 1.46 9.83 ± 1.99 9.83 ± 1.60 9.50 ± 1.22 9.67 ± 2.42 11.50 ± 1.38 11.67 ± 0.82 11.67 ± 0.82 9.6 ± 1.8 8.8 ± 1.7 6.3 ± 1.6 4.6 ± 1.8*† 1.1 ± 0.7# ** 10.6 ± 1.2‡‡§||
SVR (dyne/s/
cm5)
1123 ± 346 912 ± 263 947 ± 323 913 ± 288 857 ± 249 1195 ± 475 1532 ± 460† 1755 ± 522† § 1199 ± 246 971 ± 382 1040 ± 377 1081 ± 352 1323 ± 301 870 ± 258 ##
Abbreviations: B: Basal; D: Dobutamine; CO: Cardiac Output; SV: Stroke Volume; HR: Heart Rate; MAP: Mean Arterial Pressure; CVP: Central Venous Pressure; SVR: Systemic Vascular Resistances. AVP: Arginine-
vasopressin.
Significance at repeated measures analysis of variance. *p < 0.05 vs. B1-3.
†p < 0.001 vs. B1-3. Significance at repeated measures analysis of variance. *p < 0.01 vs. B4.
†p < 0.001 vs. B4.
‡p < 0.05 vs. B4.
§p < 0.05 vs.
AVP1. Significance at repeated measures analysis of variance. *p < 0.01 vs. B5.
†p < 0.05 vs. H1.
‡p < 0.001 vs. H2.
§p < 0.001 vs. H3.
||p < 0.001 vs. H4.
#p < 0.001 vs. B5. **p < 0.001 vs. H1.
††p < 0.01 vs. H1.
‡‡p < 0.05
vs. H2.
§§p < 0.05 vs. B5.
||||p < 0.01 vs. H1.




















All recorded CDI™ sensor-related values for pH have
been plotted versus the corresponding laboratory blood gas
analyzer according to Bland-Altman analysis (Figure 2 C)
and showed a very minimal bias and precision of -0.001
and 0.01pH units, respectively (r2 = 0.96).
The analysis of the different hemodynamic phases
including all measurements showed very good agreement
for SO2 (Figure 1D, bias 0.04, precision 0.33, r
2 = 0.95),
Base excess (Figure 1E, bias 0.04, precision 0.28,
r2 = 0.98), HCO3 (Figure 1F, bias 0.05, precision 0.62,
r2 = 0.92), hemoglobin (Figure 1G, bias 0.02, precision
0.23, r2 = 0.96) and K+ (Figure 1H, bias 0.02, precision
0.27, r2 = 0.93). The sub-analysis of K+ during hemor-
rhage showed a good agreement in H1 and H2 while in
H3 and H4 although the agreement was lower, the corre-
lation was still significant (p = 0.02).
Table 2 Pearson Correlation Coefficient and Bland-Altman analysis
All B1-3 D1-2 AVP1-3 H1 H2 H3 H4 VR
Ph
r2* 0.9604 0.9216 0.9025 0.8649 0.9776 0.8441 0.9781 0.9409 0.9604
Bias -0.001 -0.01 0.002 -0.01 0.004 0.01 -0.001 -0.008 -0.003
Precision 0.01 0.009 0.023 0.02 0.02 0.01 0.008 0.009 0.01
LoA -0.03 to 0.03 0.02 to 0.01 -0.04 to 0.04 -0.04 to 0.03 -0.04 to 0.03 -0.01 to 0.04 -0.01 to 0.01 -0.02 to 0.01 -0.02 to 0.01
BE
r2* 0.9801 0.9216 0.9744 0.9929 0.9925 0.9801 0.9801 0.9444 0.9801
Bias -0.04 0.08 0.05 -0.01 -0.01 -0.03 -0.02 -0.07 0.02
Precision 0.28 0.33 0.31 0.10 0.12 0.26 0.32 0.29 0.3
LoA -0.61 to 0.58 -0.57 to 0.74 -0.6 to 0.6 -0.24 to 0.27 -0.35 to 0.33 -0.30 to 0.33 -0.36 to 0.51 -0.45 to 0.40 -0.5 to 0.5
pO2
r2* 0.9604 0.9409 0.9025 0.9216 0.9409 0.8724 0.8134 0.8649 0.9604
Bias -0.06 -0.09 -0.09 -0.11 -0.02 -0.10 -0.04 -0.10 0.01
Precision 0.22 0.13 0.16 0.16 0.24 0.31 0.23 0.27 0.11
LoA -0.28 to 0.36 -0.30 to 0.37 -0.26 to 0.29 -0.42 to 0.58 -0.4 to 0.30 -0.23 to 0.26 -0.45 to 0.42 -0.18 to 0.27 -0.42 to 0.49
pCO2
r2* 0.9560 0.9246 0.7241 0.9036 0.9909 0.9409 0.9281 0.9744 0.9801
Bias 0.02 -0.05 -0.12 0.04 -0.01 0.06 0.02 0.08 0.07
Precision 0.15 0.27 0.54 0.09 0.09 0.06 0.15 0.18 0.19
LoA -0.24 to 0.33 -0.21 to 0.15 -0.61to 0.49 -0.13 to 0.22 -0.04 to 0.14 -0.15 to 0.18 -0.25 to 0.30 -0.12 to 0.20 -0.14 to 0.22
SaO2
r2* 0.9564 0.9725 0.9744 0.9241 0.9755 0.9925 0.9056 0.9929 0.9464
Bias 0.04 -0.02 -0.01 -0.88 -0.02 0.01 0.04 0.01 0.04
Precision 0.33 0.34 0.33 0.41 0.20 0.30 0.34 0.26 0.2
LoA -0.6 to 0.7 -0,2 to 0.5 -0.1 to 0.3 -0.3 to 0.6 -0.08 to 0.3 -0.07 to 0.2 -0.6 to 0.6 -0.08 to 0.23 -0.3 to 0.3
HCO3
r2* 0.9201 0.8724 0.8976 0.9025 0.9241 0.9604 0.9329 0.9604 0.9801
Bias 0.05 0.09 0.08 0.06 0.07 -0.18 0.07 0.18 0.11
Precision 0.62 0.69 0.51 0.70 0.62 0.64 0.59 0.42 0.45
LoA -1.1 to 1.2 -1.2 to 1.4 -1.1 to 1.0 -1.2 to 0.7 -1.2 to 1.5 -1.4 to 1.0 -1.3 to 1.5 -0.6 to 1.0 -0.7 to 1.1
Hb
r2* 0.9601 0.9849 0.9801 0.9836 0.9804 0.9649 0.9216 0.9649 0.9801
Bias 0.02 0.02 0.03 0.03 0.01 0.02 0.05 0.01 0.01
Precision 0.23 0.30 0.22 0.30 0.13 0.27 0.42 0.18 0.2
LoA -0.2 to 0.2 -0.2 to 0.3 -0.1 to 0.2 -0.5 to 0.6 -0.1 to 0.1 -0.1 to 0.1 -0.6 to 0.6 -0.2 to 0.2 -0.1 to 0.1
K+
r2* 0.9364 0.9941 0.9869 0.9569 0.9329 0.8836 0.7281 0.7056 0.8464
Bias 0.02 0.01 -0.02 0.03 -0.04 -0.05 0.06 0.10 0.05
Precision 0.27 0.12 0.34 0.29 0.32 0.33 0.49 0.59 0.34
LoA -0.3 to 0.3 -0.2 to 0.2 0.4 to 0.4 -0.3 to 0.3 -0.3 to 0.4 -0.5 to 0.5 -0.5 to 0.5 -0.8 to 0.8 -0.4 to 0.4
Abbreviations: B: Basal; DBT: Dobutamine; AVP: Arginine-vasopressin; H: Hemorrhage; VR: Volume Resuscitation;; BE: Base Eccess ( meq/L); pO2: Partial Pressure of
Oxygen (KPascal); pCO2: Partial Pressure of Carbon-dioxide (KPascal); SaO2: Oxygen saturation; (%) HCO3: Bicarbonate (meq/L); Hb: Hemoglobin (g/dL);
K+:: Potassium ione (mmole/L).
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Discussion
Management of critically ill patients requires frequent
arterial blood gas analyses in the assessment of respira-
tory and hemodynamic function [2,11]. The current
standard for blood gas analysis is intermittent blood gas
sampling with measurements performed in vitro, in a
blood gas analyzer [12]. Nonetheless, intermittent arter-
ial blood gas analysis provides only snapshots of infor-
mation about the patient’s status, may involve a
significant turnaround time, exposes the health-care
professionals to the patient’s blood and results in iatro-
genic blood loss [1,13,14].
Several attempts have been made to overcome the dis-
advantages of intermittent arterial blood sampling and
to develop a real-time continuous blood gas monitoring
system.
Furthermore, pulse oximetry, capnometry and transcuta-
neous blood gas measurement cannot fully replace arterial
pO2, arterial pCO2 and arterial pH analyses in the clinical
setting because of their significant limitations[15-20].
Advances in optical sensor technology have allowed
the development of devices that can monitor blood gas
levels using optical sensors (optodes) [21]. The extra-
arterial blood gas (EABG) monitors such as the CDI™
2000 (3M Healthcare, Tustin, CA) are on-demand sys-
tems which utilize optodes which are externally attached
to the arterial catheter. Although studies have demon-
strated their accuracy and precision compared with con-
ventional blood gas analyzers [22,23], the on-demand
monitoring systems are not continuous and the rate of
measurements is operator-dependent.
Unlike EABG systems, intra-arterial blood gas (IABG)
monitors have the sensors placed into the arterial blood
stream. Contrasting results have been reported about
the reliability of their clinical performance[24-32] and
their consistency and reliability are argued because of
the brittleness of the fibers [33] and their drawbacks
related to the intra-arterial environment and the indwel-
ling sensor (wall effect, kinking and bending impact of
wrist position) [1]. Although significant improvement in
the performance of the new IABG monitors have been
reported [34,35], concerns still remain about the accu-
rateness of pO2 analysis especially during hemodynamic
instability [33].
The CDI™ 500 (Terumo Cardiovascular Systems Cor-
poration, Ann Arbor MI) is a microprocessor-based
monitor which uses an optical fluorescence technology
to measure blood gases, pH and potassium. In addition
it employs an optical reflectance technology to measure
oxygen saturation, hematocrit and hemoglobin. This sys-
tem is widely employed for continuous blood gas moni-
toring during cardiopulmonary bypass [4,5,36,37]. As far
as we are aware, it has never been employed for contin-
uous bedside monitoring of blood gases.
Therefore we tested the “off label” use of this device
in a preclinical model in different hemodynamic condi-
tions for a future investigation in the clinical practice.
The Clinical Laboratory Improvement Amendments
for in vitro arterial blood gas analyzers (CLIA) of 1988
[38] indicates limits of precision as follows: pH: ± 0.04;
pCO2: ± 0.66 (4.9) kPa (mmHg); pO2: ± 8%. In this
study, the sensor showed excellent performance, with
values lower than the CLIA limits. Furthermore, even
though results are difficult to compare because of dif-
ferent study design, different sites of sensor placement
(radial artery, femoral artery or brachial artery) and
dissimilar length of measurements, our figures com-
pare favorably with data reported in the literature
[22,34,39-41].
It has been shown that pO2 is the most flow-dependent
variable [34] and IABG monitors may not always be
accurate in determination of arterial blood oxygenation
Figure 2 Bland Altman plots showing all measurements. Data
are plotted as differences versus means for (A) pO2 (Partial Pressure
of Oxygen). (B) pCO2 (Partial Pressure of Carbon-dioxide). (C) pH.
(D) SaO2 (Oxygen saturation). (E) BE (Base Eccess). (F) HCO3
(Bicarbonate). (H) K+(Potassium ione) (G) Hb (Hemoglobin). The
solid lines represent the Bias the dashed lines the precision (± 2 SD)
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especially during hemodynamic instability [33]. Indeed,
the improvement in the accuracy of pO2 measurements
is an important focus for the development of such equip-
ment. In our experience, the CDI™ 500, whatever the
test conditions, showed a good agreement with the inter-
mittent gas analysis. We showed similar results for Base
Excess (precision,0.28), SO2 (precision,0.33), HCO3 (pre-
cision,0.62), Hemoglobin (precision,0.23) and potassium
(precision,0.27). Finally, the precision was maintained
throughout the study and under disparate cardiocircula-
tory stress conditions
The CDI™ 500 was easy to set up and to calibrate
and it did not need re-calibration. In contrast, the avail-
able systems for continuous blood gas monitoring
require re-calibration (using in vitro laboratory gas
determinations) after prolonged monitoring in the clini-
cal setting according to the recommendations of the
manufacturer. However, the issue of re-calibration was
not discussed in previous studies, and it was performed
at different time points [34].
Furthermore, because of the heparin-treated sensor,
there was no need for a continuous heparinised saline
flush, necessary in intra-vascular systems to maintain
the patency of the circuit [1].The flush solution, at room
temperature, contains dissolved oxygen and carbon
dioxide at partial pressures similar to that of the atmo-
sphere thus it may alter the local gas tension. As a con-
sequence, the system may measure the blood gas
variables in the flush solution, resulting in errors known
as the “flush effect” [1,42]. The CDI™ 500 was highly
reliable even when the flow decreased significantly dur-
ing vasoconstriction in contrast with IABG systems
which are susceptible to blood flow and when it is low
or stops measurements become unreliable [1].
Perspective of Clinical Application
In our opinion CDI™ 500 might be extremely useful in
the clinical setting, particularly in patients with low car-
diac output, requiring a close monitoring. In these cases,
CDI 510H sensoring device would be advisably inserted
in a femoral artery-to-vein configuration to maintain a
35 ml/min flow through the circuit. In patients with
preserved cardiac output it is possible to design a radial
artery-to-any vein configuration provided that the vein
catheter is at least a 16-gauge (internal jugular catheter)
to guarantee an optimal intra-device flow.
Finally, it must be taken into consideration that such a
methodology might be applied for continuous and on-
line monitoring particularly in severely critical patients,
like the ones on cardiocirculatory support (Extracorpor-
eal Membrane Oxygenation or Ventricular Assist
Devices). In these circumstances, CDI circuit can be
instrumented either along the arterial or the vein
ECMO circuit line to continuously measure blood
parameter enabling a real-time appraisal of ongoing effi-
cacy of peripheral perfusion and, thus, a prompt warn-
ing and call for reassessment in case of suboptimal
parameters without waiting the next external blood gas
analysis.
Nonetheless further studies will be required to make
this device into a viable clinical approach. In particular
the following issues need to be addressed:
a) The true advantages of this system over intermittent
or near-continuous monitoring in terms of blood loss,
need for erythrocyte transfusions (especially in infant and
children)and the risk of nosocomial infections.
b) The hazards of arterio-venous shunting of blood
especially of clinical importance in critically ill patients
with low cardiac output.
c) The accuracy of the device and need for re-calibra-
tion after use for long times.
d) Need of heparinization should be further investi-
gated before a devices’ routine clinical use, though, in
the present experience, we had no clotting-related
problems
Limitations
Our study presents some limitations that should be
pointed out:
First, optode devices intrinsically have lower signal to
noise ratio at higher PO2; thus the
nice agreement shown here for a lower range of PO2
may not hold up as well in
a high range. For this reason our findings are not fully
comparable with prior studies
that did investigate a full range of PaO2.
Second, cost effectiveness is an important issue when
new monitoring devices are introduced in the clinical
practice. No cost-benefit analysis was carried out in this
study and is subject of ongoing research.
Conclusions
On the basis of our experience we can conclude that
continuous blood gas analysis with the CDI™ 500 sys-
tem was practical, accurate and reproducible. It might
represent a new useful tool to monitor gas exchange in
critically ill patients, even on mechanical circulatory
support, and during anesthesia for major surgery. None-
theless our findings need to be confirmed by larger stu-
dies to prove its reliability in the clinical setting.
Key Messages
• Intermittent gas analysis may provide only a snap-
shot of blood gases fluctuations occurring even in
stable patients in the intensive care unit.
• The extra-arterial blood gas monitors are not con-
tinuous and the rate of measurements is operator-
dependent.
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• The intra-arterial blood gas monitors present some
drawbacks related to the intra-arterial environment
and the indwelling sensor.
• The CDI™ Blood parameter monitoring system
500 is an optical fluorescence and reflectance-based
in-line system which is used during cardiopulmonary
bypass
• The “off label” use of The CDI™ 500 in a preclini-
cal model was reliable. Thus it might represent a
new useful tool to accurately and timely monitor gas
exchange in critically ill patients.
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